Framycetin: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Indonesia prescribing information.

Generic Medicine Info

Indications and Dosage

Ophthalmic
Bacterial conjunctivitis, Blepharitis, Corneal abrasion, Stye

Adult: As 0.5% solution or ointment: For rapid relief in acute conditions: Instill 1-2 drops to affected eye(s) 1-2 hourly for the 1st 2-3 days. Reduce to 1-2 drops 3-4 times daily when there is improvement.
Child: Same as adult dose.

Otic/Aural
Otitis externa

Adult: As 0.5% solution: Instill 2-3 drops into the external auditory meatus tid. Max treatment duration: 2 weeks.
Child: Same as adult dose.

Topical/Cutaneous
Burns, Skin infections, Skin ulcer, Skin wound

Adult: As dressing containing framycetin 1%: Apply a single layer directly to the wound. Change the dressing at least daily if wound is exudative. For leg ulcers, cut the dressing accurately to size of ulcer to avoid contact with surrounding healthy skin and to reduce the risk of sensitisation.

Contraindications

Hypersensitivity to framycetin or other aminoglycoside antibacterials (neomycin, kanamycin). Perforated tympanic membrane (otic).

Special Precautions

Children. Pregnancy and lactation.

Adverse Reactions

Significant: Bacterial or fungal superinfection (prolonged use).
Ear and labyrinth disorders: Inner ear damage.
Eye disorders: Eye irritation, superficial punctate keratitis, delayed corneal epithelial wound healing, retinal toxicity (if there is leakage through corneoscleral wound).
Immune system disorders: Hypersensitivity reactions.

Patient Counseling Information

Ophthalmic: This drug may cause blurred vision, if affected, do not drive or operate machinery. If you are wearing contact lenses, remove prior to application and reinsert after 15 minutes.

Monitoring Parameters

Monitor improvement of infection/symptoms.

Action

Description:
Mechanism of Action: Framycetin is an aminoglycoside bactericidal antibiotic. Its exact mechanism of action has not been fully elucidated; however, it appears to inhibit protein synthesis in susceptible bacteria by binding to ribosomal subunits. Framycetin is active against many aerobic gram-negative bacteria and some aerobic gram-positive bacteria.

Chemical Structure

Storage

Store between 15-25°C.

MIMS Class

Ear Anti-Infectives & Antiseptics / Eye Anti-Infectives & Antiseptics / Topical Antibiotics

ATC Classification

D09AA01 - framycetin ; Belongs to the class of ointment dressings with antiinfectives.
S01AA07 - framycetin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.

References

Anon. Framycetin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/11/2019 .

Buckingham R (ed). Framycetin Sulfate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2019 .

Joint Formulary Committee. Framycetin Sulfate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/11/2019 .

Rossi S (ed). Framycetin (Ear). Australian Medicines Handbook [online]. Adelaide. Australian Medicines Handbook Pty Ltd. https://amhonline.amh.net.au. Accessed 11/11/2019 .

Rossi S (ed). Framycetin (Eye). Australian Medicines Handbook [online]. Adelaide. Australian Medicines Handbook Pty Ltd. https://amhonline.amh.net.au. Accessed 11/11/2019 .

Sanofi-Aventis New Zealand Limited. Soframycin 5 mg/mL Ear/Eye Drops data sheet 25 January 2018. Medsafe. http://www.medsafe.govt.nz/. Accessed 11/11/2019 .

Disclaimer: This information is independently developed by MIMS based on Framycetin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com